ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.
Our Board of Governors has appointed Mark Roithmayr as Chief Executive Officer. Mr. Roithmayr is the first person to hold the CEO position at the ADDF.
We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.
On Monday, November 14, Donald Newhouse received The Charles Evans Award from the Alzheimer’s Drug Discovery Foundation (ADDF) at our Seventh Annual Fall Symposium & Luncheon "Hope on the Horizon" at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.
The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million.
Alzheimer’s Drug Discovery Foundation Launches Expanded Brain Health and Dementia Prevention Website
The streamlined site separates fact from fiction and empowers people to make smarter choices for their brain health.
Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF, says: “The ADDF is proud to support a clinical trial that holds such promise for Alzheimer’s patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer’s.”
Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death
Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.
With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.